“Patent Thickets” are Anti-Competitive and Lead to Higher Drug Costs
Patent thickets are a drug manufacturer’s strategy that keeps competitor products off the market and reduces PBMs’ ability to negotiate savings.
Patent thickets are a drug manufacturer’s strategy that keeps competitor products off the market and reduces PBMs’ ability to negotiate savings.
Pharmacy benefit companies actively promote the use of generics and biosimilars. Take a look at the data on drug utilization: 90 percent of prescriptions dispensed are generics or biosimilars. During last week’s hearing in the House Oversight Committee, Dr. Rena
Study Finds Yearly Cost of Patent Thickets on Five Top-Selling Brand Name Drugs Ranges from $1.8 to $7.6 Billion In case you missed it, a new report from The Coalition for Affordable Prescription Drugs (CAPD) and conducted by Matrix Global
In case you missed it, a new report from health policy researcher Alex Brill, founder and CEO of Matrix Global Advisors and former policy director and chief economist for the U.S. House Committee on Ways and Means, “Rebates and Drug
Last week, the U.S. House Ways and Means Committee Health Subcommittee held a hearing on “Why Health Care is Unaffordable: Anticompetitive and Consolidated Markets.” During the hearing, Congressman Kevin Hern (R-OK) shared that, as a former business owner, he was
With so many important issues being debated today, there are few topics that health care, legal, and economic experts agree on. But the fact that drug companies are the root cause of high prescription drug prices is one common denominator
Upcoming Events Events 10 Nov 10 Nov – 11 Nov Test 2021-11-10 01:00 AM – 2021-11-11 03:00 AM Online Event PCMA Spring Webinar Series 2020 The live webinar series is designed to highlight drug supply chain executives’ thoughts and strategies
With the recent launch of a new adalimumab biosimilar, the U.S. biosimilar market is becoming more competitive, increasing the potential for these more affordable options to play a critical role in helping to lower prescription drug costs for Americans. As biosimilar competition
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott issued the following statement on the Health and Human Services Officer of Inspector General report (OIG) on prescription drug rebates in Medicare Part D. “Today’s OIG report
For millions of Americans, the prescription drug delivery system works: people, for the most part, can access the medications they need when they need them, and at the cost they expect and can afford. But “millions of Americans” does not
©2022 PCMA. All Rights Reserved.